Erratum: Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2- Metastatic Breast Cancer - European Medical Journal

This site is intended for healthcare professionals

Erratum: Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2- Metastatic Breast Cancer

Oncology

Author: EMJ

Citation: EMJ Oncol. 2026; https://doi.org/10.33590/emjoncol/7O084YQK

Date correction published: 17/03/2026

Original publication¹

In the symposium review article published under EMJ Oncology on 23rd January 2026, reference 8 was missing from the text. This has now been added in the first paragraph.

EMJ apologise(s) for the error and any inconvenience caused.

Reference:

1. Scott B. Strategic Treatment Sequencing and Novel Approaches in 2L+ ER+/HER2- Metastatic Breast Cancer. EMJ Oncology. 2025;14[Suppl 1]:2-12.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.